Bowdle T A
Department of Anesthesiology, University of Washington, Seattle 98195, USA.
Drug Saf. 1998 Sep;19(3):173-89. doi: 10.2165/00002018-199819030-00002.
The traditional view of opioids held that the individual opioid agonists shared the same mechanism of action, differing only in their potency and pharmacokinetic properties. However, recent advances in opioid receptor pharmacology have made this view obsolete. Distinguishing features of the synthetic opioid agonists are related, at least in part, to variation in affinity and intrinsic efficacy at multiple opioid receptors. Respiratory depression is the opioid adverse effect most feared by anaesthesiologists. Specific kappa-receptor agonists produce analgesia with little or no respiratory depression. There are a number of commercially available kappa-receptor partial agonist drugs, the so-called agonist-antagonist or nalorphine-like opioids, which appear to have a limited effect on breathing. Within the series of fentanyl analogues there are differences in behaviour towards particular opioid receptors and there is evidence for subtle differences in respiratory depressant effects. Pethidine (meperidine) causes histamine release and myocardial depression, while the fentanyl analogues do not. Pethidine has atropine-like effects on heart rate, while fentanyl analogues reduce heart rate by a vagomimetic action. Severe bradycardia or even asystole is possible with fentanyl analogues, especially in conjunction with the vagal stimulating effects of laryngoscopy. Fentanyl analogues often produce minor reductions in blood pressure, and occasionally severe hypotension by centrally mediated reduction in systemic vascular resistance. Muscle rigidity and myoclonic movement occurs frequently during induction of anaesthesia with larger doses of opioids. Fentanyl and alfentanil have been reported to produce localised temporal lobe electrical seizure activity in patients with complex partial epilepsy. There are probably fewer biliary effects with agonist-antagonist opioids than the agonist opioids. The mechanism of adverse effects after spinal administration is distinctly different for morphine, which is very water soluble, compared with more lipid-soluble opioids. The systemic absorption of morphine after intrathecal or epidural administration is very slow, resulting in long duration of analgesia and low plasma concentrations, while lipid-soluble opioids are rapidly absorbed into the circulation and redistributed to the brain. The serotonin syndrome may result from coadministration of pethidine, dextromethorphan, pentazocine or tramadol with monoamine oxidase inhibitors (MAOIs) or selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs). There are clinically important interactions between opioids and hypnosedatives, resulting in synergistic effects on sedation, breathing and blood pressure.
传统的阿片类药物观点认为,各个阿片类激动剂具有相同的作用机制,只是在效力和药代动力学特性上有所不同。然而,阿片受体药理学的最新进展已使这一观点过时。合成阿片类激动剂的显著特征至少部分与多种阿片受体的亲和力和内在活性变化有关。呼吸抑制是麻醉医生最担心的阿片类药物不良反应。特定的κ受体激动剂产生镇痛作用,几乎不引起或完全不引起呼吸抑制。有多种市售的κ受体部分激动剂药物,即所谓的激动 - 拮抗剂或纳洛啡样阿片类药物,它们对呼吸的影响似乎有限。在芬太尼类似物系列中,对特定阿片受体的作用存在差异,并且有证据表明呼吸抑制作用存在细微差别。哌替啶(度冷丁)会引起组胺释放和心肌抑制,而芬太尼类似物则不会。哌替啶对心率有类似阿托品的作用,而芬太尼类似物通过拟迷走神经作用降低心率。使用芬太尼类似物时可能会出现严重心动过缓甚至心脏停搏,尤其是与喉镜检查的迷走神经刺激作用同时发生时。芬太尼类似物通常会使血压轻度降低,偶尔会因中枢介导的全身血管阻力降低而导致严重低血压。在使用大剂量阿片类药物诱导麻醉期间,肌肉强直和肌阵挛运动经常发生。据报道,芬太尼和阿芬太尼会使复杂部分性癫痫患者出现局部颞叶癫痫样放电活动。激动 - 拮抗剂类阿片药物的胆道效应可能比激动剂类阿片药物少。与脂溶性更高的阿片类药物相比,水溶性极高的吗啡在脊髓给药后的不良反应机制明显不同。鞘内或硬膜外给药后,吗啡的全身吸收非常缓慢,导致镇痛时间长且血浆浓度低,而脂溶性阿片类药物则迅速吸收进入循环并重新分布到脑部。与单胺氧化酶抑制剂(MAOIs)或选择性5-羟色胺(5-羟色胺;5-HT)再摄取抑制剂(SSRIs)同时使用哌替啶、右美沙芬、喷他佐辛或曲马多可能会导致5-羟色胺综合征。阿片类药物与催眠镇静药之间存在具有临床重要性的相互作用,会对镇静、呼吸和血压产生协同作用。